Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy in Early- and Late-Stage Cancers
Data from 20 abstracts demonstrate value of company’s blood tests across the continuum of cancer care, including: screening, therapy selection, residual and recurrent disease detection, and biopharmaceutical drug development REDWOOD CITY, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), to present data demonstrating the use of the company’s proprietary blood tests to advance precision oncology, including cancer […]